Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In the Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban 20 mg was the on-label dose, and the dose-reduction criterion for rivaroxaban was a creatinine clearance of < 50 mL/min. Some Asian countries are using reduced doses label according to the J-ROCKET AF trial. The aim of this study was to assess the safety and efficacy of a high-dose rivaroxaban regimen (HDRR, 20/15 mg) and low-dose rivaroxaban regimen (LDRR, 15/10 mg) among elderly East Asian patients with atrial fibrillation (AF) in real-world practice.
Methods: This study was a multicenter, prospective, non-interventional observational study designed to evaluate the efficacy and safety of rivaroxaban in AF patients > 65 years of age with or without renal impairment.
Results: A total of 1,093 patients (mean age, 72.8 ± 5.8 years; 686 [62.9%] men) were included in the analysis, with 493 patients allocated to the HDRR group and 598 patients allocated to the LDRR group. A total of 765 patients received 15 mg of rivaroxaban (203 in the HDRR group and 562 in the LDRR group). There were no significant differences in the incidence rates of major bleeding (adjusted hazard ratio [HR], 0.64; 95% confidential interval [CI], 0.21-1.93), stroke (adjusted HR, 3.21; 95% CI, 0.54-19.03), and composite outcomes (adjusted HR, 1.13; 95% CI, 0.47-2.69) between the HDRR and LDRR groups.
Conclusion: This study revealed the safety and effectiveness of either dose regimen of rivaroxaban in an Asian population for stroke prevention of AF. Considerable numbers of patients are receiving LDRR therapy in real-world practice in Asia. Both regimens were safe and effective for these patients.
Trial Registration: ClinicalTrials.gov Identifier: NCT04096547.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911935 | PMC |
| http://dx.doi.org/10.3346/jkms.2024.39.e72 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial Intelligence Automation of Echocardiographic Measurements.
J Am Coll Cardiol
August 2025
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, USA. Electronic address:
Background: Accurate measurement of echocardiographic parameters is crucial for the diagnosis of cardiovascular disease and tracking of change over time; however, manual assessment requires time-consuming effort and can be imprecise. Artificial intelligence has the potential to reduce clinician burden by automating the time-intensive task of comprehensive measurement of echocardiographic parameters.
Objectives: The purpose of this study was to develop and validate open-sourced deep learning semantic segmentation models for the automated measurement of 18 anatomic and Doppler measurements in echocardiography.
Ethanol Infusion of the Vein of Marshall in Catheter Ablation of Persistent Atrial Fibrillation in Patients with Mitral Valve Replacement.
Heart Rhythm
September 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China. Electronic address:
Background: The effectiveness of ethanol infusion of the vein of Marshall (EIVOM) for persistent atrial fibrillation (AF) in patients with mitral valve replacement (MVR) remains to be determined.
Objectives: This study investigated the effectiveness and safety of EIVOM in catheter ablation of persistent AF in patients with MVR.
Methods: This is a retrospective case-control study.
Key messages on subclinical atrial fibrillation from the ARTESiA and NOAH trials.
Rev Esp Cardiol (Engl Ed)
September 2025
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Evaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants.
J Pharm Pract
September 2025
Department of Pharmacy, Houston Methodist Hospital, TX, USA.
Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation).
View Article and Find Full Text PDFBipolar radiofrequency ablation for refractory scar-related interatrial septal tachycardias: a multicenter study.
J Interv Card Electrophysiol
September 2025
Electrophysiology Section, Cardiovascular Division, Cleveland Clinic, Cleveland, OH, USA.
Background: Catheter ablation of scar-related interatrial septal atrial tachycardias (IAS-ATs) is challenging and can be refractory to conventional unipolar radiofrequency catheter ablation (RFCA).
Aim: This multicenter study investigated the safety and efficacy of bipolar radiofrequency catheter ablation (Bi-RFCA) in patients with IAS-AT refractory to conventional unipolar RFCA.
Methods: Consecutive patients with scar-related IAS-AT refractory to conventional unipolar RFA across three electrophysiological centers were included in the study.